Par Wants Bulk Vasopressin Compounding Nixed; FDA Agrees
Just as Par Pharmaceutical asked a D.C. federal court Monday to enjoin a U.S. Food and Drug Administration policy governing bulk drug compounding, the agency agreed the same day that the...To view the full article, register now.
Already a subscriber? Click here to view full article